Research is a big part of my career. I established the thrombotic microangiopathy research program, which studies rare blood diseases including thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic-uremic syndrome (HUS). I’m also involved in the design and execution of several international clinical trials.
I enjoy working alongside world-class medical experts at The James to improve patient care. The collaborative environment among physicians and staff at The OSUCCC – James is what truly sets it apart from other cancer centers.
My work has received widespread recognition. I’ve been published in national and international medical journals, including the New England Journal of Medicine, Blood, and, the Journal of Thrombosis and Haemostasis.
Ohio State University College of Medicine
Ohio State University Wexner Medical Ctr
7/1/1995 - 6/30/1997
Specialties and conditions I treat
- Benign Hematology
- Hemolytic-Uremic Syndrome
- Thrombotic Microangiopathies
- Purpura, Thrombotic Thrombocytopenic
Locations where I practice
JamesCare at University Hospital East
More about my work
University of Chicago Hospitals
7/1/1997 - 6/30/2000
American Board of Internal Medicine
American Board of Internal Medicine (Subspecialty: Hematology)
American Board of Internal Medicine (Subspecialty: Medicine Oncology)
News about me
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/25/2016, Dr. Cataland has reported no financial relationships with medical device, research and/or drug companies.